Free Newsletter
Tech guns aim at counterfeiters
Sophisticated quality measurement technologies, as well as multinational investigative and research efforts, are being marshaled to ensure the quality of drugs, says the Canadian Health Products and Food Branch. Some 300 attendees from 26 countries heard of the government's efforts at the annual scientific meeting of the U.S. Pharmacopeial (USP) Convention in Toronto.
Tactical sophistication is clearly warranted: the profit margin on fake Viagra was estimated to be 2,000 times that for cocaine, according to ASM speakers. And although many people believe in the safety of drugs purchased from online pharmacies calling themselves "Canadian," that belief is unfounded: There are more than 11,000 such sites, with just 214 actually registered in Canada. And it turns out that the search term "Canadian pharmacy" is one of the world's biggest spam generators.
Likewise, speakers at the upcoming Next Generation Pharma (NGP) Summit are expected to describe how drug makers are turning to nanotechnologies, labeling specialists, RFID and asset tracking experts in attempts to foil counterfeiters and protect their brands.
The speakers should find a receptive audience: Some 75 percent of life sciences executives in a recent IBM survey identified the monitoring risk to prevent counterfeiting and recalls a priority, as margins become slimmer and supply chain complexity rises. Three-quarters of respondents say they have risk and performance initiatives in place, including surveillance programs, anti-tamper devices and specialized labeling, but are experiencing mixed results.
- here's the USP meeting recap
- see the NGP item
- read the IBM survey announcement
Related Articles:
Drug supply changes imminent
Hamburg details actions on fake H1N1 cures
FDA seeks input on anticounterfeiting guidance
Counterfeiting concerns rise, but cost concerns rule
Anticounterfeiting group hits the fast lane
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline

SHARE
WITH: